COLL · XBRL financial data

Collegium Pharmaceutical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (COLL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	310	277	464	567	631	781
Cost of goods and services sold	130	126	254	241	254	317
Gross profit	180	151	209	326	377	463
Research and development	10	9	4	0	0	—
Selling, general and administrative	114	119	172	159	210	285
Total operating expenses	124	133	176	159	207	284
Operating income (loss)	56	18	33	167	170	180
Interest expense	29	21	63	83	74	82
Income tax expense (benefit)	1	(75)	(4)	28	29	30
Net income (loss)	27	72	(25)	48	69	63
Earnings per share, basic USD per share	0.78	2.05	(0.74)	1.43	2.14	1.98
Earnings per share, diluted USD per share	0.76	1.86	(0.74)	1.29	1.86	1.73
Weighted average shares, basic millions of shares	34	35	34	34	32	32
Weighted average shares, diluted millions of shares	35	41	34	42	40	40

Fiscal years (COLL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	174	186	174	239	71	231
Marketable securities	—	—	0	72	92	155
Accounts receivable	83	106	183	180	229	211
Inventory	16	17	47	32	36	41
Prepaid and other current assets	5	6	17	15	30	33
Total current assets	278	316	420	538	482	691
Property and equipment, net	19	19	20	16	14	12
Right-of-use asset	8	8	7	6	6	4
Goodwill	—	—	134	134	162	146
Total assets	644	692	1,174	1,143	1,664	1,657
Accounts payable	10	4	3	9	4	11
Accrued liabilities	25	29	36	38	72	62
Total current liabilities	239	280	434	458	510	440
Lease liability, non-current	9	8	7	6	6	4
Total liabilities	458	489	979	948	1,435	1,355
Accumulated deficit	(333)	(256)	(281)	(233)	(164)	(101)
Total stockholders' equity	186	203	195	195	229	302
Total liabilities and equity	644	692	1,174	1,143	1,664	1,657
Common shares outstanding (cover page) millions of shares	35	33	34	32	31	32

Fiscal years (COLL's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	27	72	(25)	48	69	63
Stock-based compensation	22	24	23	27	32	42
Net cash from operating activities	94	104	124	275	205	329
Purchases of property and equipment	6	2	2	0	2	2
Net cash from investing activities	(374)	(2)	(574)	(71)	(288)	(64)
Share repurchases	—	48	14	75	60	25
Repayments of long-term debt	12	—	—	—	—	—
Net cash from financing activities	286	(89)	437	(140)	(61)	(110)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Viridian Therapeutics	173	26	not reported	113.6M	—	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Akebia Therapeutics	156	49	3.5*	277.1M	—	Q2 FY26 10-QJun 30, 2026
Neogen	172	223	13	218.3M	—	Q1 FY27 10-QAug 31, 2026
Intellia Therapeutics	106	7.7	(83)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	63	57	(16)*	642.5M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.